The FDA has approved the first focused ultrasound device to treat essential tremor in patients who have not responded to medication. ExAblate Neuro (InSightec) uses magnetic resonance (MR) images taken during the procedure to deliver focused ultrasound to destroy brain tissue in a tiny area thought to be responsible for causing tremors.
“Patients with essential tremor who have not seen improvement with medication now have a new treatment option that could help them to avoid more-invasive surgical treatments,” said Carlos Peña, PhD, MS, director of the division of neurological and physical medicine devices at the FDA’s Center for Devices and Radiological Health. “As with other treatments for essential tremor, this new device is not a cure but could help patients enjoy a better quality of life.”
Essential tremor, also called benign essential tremor, is the most common form of tremor. According to the National Institute of Neurological Disorders and Stroke, several million Americans, usually those older than 40 years of age, are affected by the condition. Essential tremor may be treated with beta blockers or anticonvulsant drugs. If medications fail to control symptoms, the condition may also be treated with surgery (thalamotomy) or with a deep-brain stimulation device to destroy the tiny part of the brain (thalamus) that controls some involuntary movements.
To determine whether the ExAblate Neuro treatment is appropriate, patients should first have MR and computerized tomography (CT) scans. Those undergoing treatment with the MRI-guided device lie in an MRI scanner that takes images to help a doctor identify the targeted area in the brain’s thalamus for treatment. Treatment with transcranial focused ultrasound energy is administered with incremental increases in energy until patients achieve a reduction of tremor. Patients are awake and responsive during the entire treatment.
Data supporting the safety and efficacy of the device system included results from a double-blind control trial involving 76 patients with essential tremor who had not responded to medication therapy. Fifty-six of the patients were randomly selected to receive the ExAblate Neuro treatment, and 20 received a sham treatment. Patients in the control group were able to cross over into the treatment group three months later.
Patients treated with the ExAblate Neuro showed a nearly 50% improvement in their tremors and motor function (composite tremor/motor function score) three months after treatment compared with their baseline score. Patients in the control group had no improvement, and some experienced a slight worsening after the sham procedure before they crossed over into the treatment group. At 12 months post-procedure, the treatment group retained a 40% improvement in these scores compared with baseline.
Adverse events for the ExAblate Neuro were consistent with those reported for thalamotomy surgery, including numbness or tingling of the fingers, headache, imbalance or unsteadiness, and ataxia or gait disturbance. Other adverse effects identified as possibly related to treatment with MR-guided focused ultrasound treatments include tissue damage in an area other than the treatment area, hemorrhage in the treated area requiring emergency treatment, skin burns with ulceration of the skin, skin retraction, scar formation, and blood clots.
The ExAblate Neuro treatment is contraindicated in patients who cannot have MR imaging, including those who have a non–MRI-compatible implanted metallic device, such as a cardiac pacemaker; those with allergies to MR contrast agents; or those with body-size limitations for MR.
In addition, the treatment should not be used in women who are pregnant; patients with advanced kidney disease or on dialysis; those with unstable heart conditions or severe hypertension; patients exhibiting any behavior consistent with ethanol or substance abuse; or patients with a history of abnormal bleeding, hemorrhage, and/or coagulopathy. Patients currently taking anticoagulant drugs or drugs known to increase the risk of hemorrhage, patients with a history of cerebrovascular disease (strokes) or brain tumors, and patients who are not able to tolerate the prolonged stationary position during treatment also should not have the procedure.
Source: FDA(link is external); July 11, 2016.
Paul Lendner ist ein praktizierender Experte im Bereich Gesundheit, Medizin und Fitness. Er schreibt bereits seit über 5 Jahren für das Managed Care Mag. Mit seinen Artikeln, die einen einzigartigen Expertenstatus nachweisen, liefert er unseren Lesern nicht nur Mehrwert, sondern auch Hilfestellung bei ihren Problemen.